Conquering Diseases

An Open Label Study Of Asciminib In Patients With Chronic Myseloid Leukemia In Chronic Phase

Description

Seeking men and women 18 years of age and older who have chronic myeloid leukemia (CML) in chronic phase (CP) with and without the T315I mutation, to determine how well the treatment with asciminib works compared to previously used therapies.

Overview

Participants in this study will receive either a low, mid or high dose of the drug asciminib. There will be about 22 different study visits over 80 weeks.

What we're hoping for

To find out if the drug asciminib is safe and has beneficial effects in people who have chronic myeloid leukemia (CML) in chronic phase (CP) with and without the T315I mutation.

Additional Information

ClinicalTrials.gov Identifier: NCT04666259

 Principal Investigator

Jan  Cerny, MD, PhD

UMass Memorial Health Care

 Study Contact

The Cancer  Research Office

508-856-3216

Cancer.research@umassmed.edu

 Location

UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989